US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.96 against a street estimate of 0.66 — a beat of 45.5%.
Analysts rate Indivior PLC Ordinary Shares a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $50.83.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.69% |
| Vanguard Portfolio Management, LLC | 6.68% |
| Oaktree Capital Management LLC | 5.91% |
| Vanguard Capital Management, LLC | 4.73% |
| State Street Corp | 4.15% |
| Two Seas Capital LP | 4.02% |
| Millennium Management LLC | 3.89% |
| Fuller & Thaler Asset Management Inc | 3.83% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 | 2026-08-03 |
| Results announced · Q3 2026 | 2026-08-03 |
| Material agreement · Q3 2026 | 2026-08-03 |
| Board / officer change · Q2 2026 | 2026-05-15 |
| Quarterly report · Q1 2026 | 2026-04-30 |
| Proxy statement · Q2 2026 | 2026-03-27 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-10-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Indivior PLC Ordinary Shares — free to start.
Google PlayApp StoreData updated 2026-08-05.